Psychopharmacology

, Volume 221, Issue 2, pp 239–247 | Cite as

Anxiogenic-like effects of chronic cannabidiol administration in rats

  • Maha M. ElBatsh
  • N. Assareh
  • C. A. Marsden
  • D. A. Kendall
Original Investigation

Abstract

Rational

Several pre-clinical and human-based studies have shown that acutely administered cannabidiol (CBD) can produce anxiolytic-like effects

Objectives

The present study investigated the effects of chronic administration of CBD on rat behaviour and on the expression of brain proteins.

Methods

Male Lister-hooded rats (150–200 g, n = 8 per group) received daily injections of CBD (10 mg/kg, i.p.) for 14 days. The rats were subjected to two behavioural tests: locomotor activity and conditioned emotional response (CER). The expression of brain-derived neurotrophic factor (BDNF), its receptor tyrosine kinase B (Trk B), extracellular signal-regulated kinases (ERK1/2) and phospho-ERK1/2 and the transcription factor cyclic AMP response element binding protein activation (CREB) and phospho-CREB were determined in brain regions such as the frontal cortex and hippocampus using Western immunoblotting.

Results

CBD significantly increased the time spent freezing in the CER test with no effect on locomotor activity. CBD significantly reduced BDNF expression in the hippocampus and frontal cortex with no change in the striatum. In addition, CBD significantly reduced TrkB expression in the hippocampus with a strong trend towards reduction in the striatum but had no effect in the frontal cortex. In the hippocampus, CBD had no effect on ERK1/2 or phospho-ERK2, but in the frontal cortex, CBD significantly reduced phospho-ERK1/2 expression without affecting total ERK.

Conclusion

Chronic administration of CBD produced an anxiogenic-like effect in clear opposition to the acute anxiolytic profile previously reported. In addition, CBD decreased the expression of proteins that have been shown to be enhanced by chronic treatment with antidepressant/anxiolytic drugs.

Keywords

Cannabidiol Anxiety BDNF ERK CREB Hippocampus Cannabinoids 

References

  1. Ashton CH (2001) Pharmacology and effects of cannabis: a brief review. Br J Psychiatry 178:101–106PubMedCrossRefGoogle Scholar
  2. Bergami M, Berninger B, Canossa M (2009) Conditional deletion of TrkB alters adult hippocampal neurogenesis and anxiety-related behavior. Commun Integr Biol 2:14–16PubMedCrossRefGoogle Scholar
  3. Bisogno T, Hanus L, De Petrocellis L, Tchilibon S, Ponde DE, Brandi I, Moriello AS, Davis JB, Mechoulam R, Di Marzo V (2001) Molecular targets for cannabidiol and its synthetic analogues: effect on vanilloid VR1 receptors and on the cellular uptake and enzymatic hydrolysis of anandamide. Br J Pharmacol 134:845–852PubMedCrossRefGoogle Scholar
  4. Bitencourt RM, Pamplona FA, Takahashi RN (2008) Facilitation of contextual fear memory extinction and anti-anxiogenic effects of AM404 and cannabidiol in conditioned rats. Eur Neuropsychopharmacol 18:849–859PubMedCrossRefGoogle Scholar
  5. Carrier EJ, Auchampach JA, Hillard CJ (2006) Inhibition of an equilibrative nucleoside transporter by cannabidiol: a mechanism of cannabinoid immunosuppression. Proc Natl Acad Sci USA 103:7895–7900PubMedCrossRefGoogle Scholar
  6. Crippa JA, Zuardi AW, Garrido GE, Wichert-Ana L, Guarnieri R, Ferrari L, Azevedo-Marques PM, Hallak JE, McGuire PK, Filho Busatto G (2004) Effects of cannabidiol (CBD) on regional cerebral blood flow. Neuropsychopharmacology 29:417–426PubMedCrossRefGoogle Scholar
  7. Dell’Osso B, Buoli M, Baldwin DS, Altamura AC (2010) Serotonin norepinephrine reuptake inhibitors (SNRIs) in anxiety disorders: a comprehensive review of their clinical efficacy. Hum Psychopharmacol 25:17–29PubMedCrossRefGoogle Scholar
  8. Duman RS, Monteggia LM (2006) A neurotrophic model for stress-related mood disorders. Biol Psychiatr 59:1116–1127CrossRefGoogle Scholar
  9. Dunn AJ, Guild AL, Kramarcy NR, Ware MD (1981) Benzodiazepines decrease grooming in response to novelty but not ACTH or beta-endorphin. Pharmacol Biochem Behav 15:605–608PubMedCrossRefGoogle Scholar
  10. Fanselow MS (1980) Conditioned and unconditional components of post-shock freezing. Pavlov J Biol Sci 15:177–182PubMedGoogle Scholar
  11. Finn DP, Beckett SRG, Richardson D, Kendall DA, Marsden CA, Chapman V (2004a) Evidence for differential modulation of conditioned aversion and fear-conditioned analgesia by CB1 receptors. Eur J Neurosci 20:848–852PubMedCrossRefGoogle Scholar
  12. Finn DP, Beckett SRG, Roe CH, Madjd A, Fone KCF, Kendall DA, Marsden CA, Chapman V (2004b) Effects of coadministration of cannabinoids and morphine on nociceptive behaviour, brain monoamines and HPA axis activity in a rat model of persistent pain. Eur J Neurosci 19:678–686PubMedCrossRefGoogle Scholar
  13. Franklin A, Stella N (2003) Arachidonylcyclopropylamide increases microglial cell migration through cannabinoid CB2 and abnormal-cannabidiol-sensitive receptors. Eur J Pharmacol 474:195–198PubMedCrossRefGoogle Scholar
  14. Gruber AJ, Pope HGJ, Brown ME (1996) Do patients use marijuana as an antidepressant? Depression 4:77–80PubMedCrossRefGoogle Scholar
  15. Guimaraes FS, Chiaretti TM, Graeff FG, Zuardi AW (1990) Antianxiety effect of cannabidiol in the elevated plus-maze. Psychopharmacology (Berl) 100:558–559CrossRefGoogle Scholar
  16. Hashimoto S, Inoue T, Koyama T (1996) Serotonin reuptake inhibitors reduce conditioned fear stress-induced freezing behavior in rats. Psychopharmacology (Berl) 123:182–186CrossRefGoogle Scholar
  17. Ignatowska-Jankowska B, Jankowski MM, Swiergiel AH (2011) Cannabidiol decreases body weight gain in rats: Involvement of CB2 receptors. Neurosci Lett 490:82–84PubMedCrossRefGoogle Scholar
  18. Inoue T, Hashimoto S, Tsuchiya K, Izumi T, Ohmori T, Koyama T (1996) Effect of citalopram, a selective serotonin reuptake inhibitor, on the acquisition of conditioned freezing. Eur J Pharmacol 311:1–6PubMedCrossRefGoogle Scholar
  19. Jarai Z, Wagner JA, Varga K, Lake KD, Compton DR, Martin BR, Zimmer AM, Bonner TI, Buckley NE, Mezey E, Razdan RK, Zimmer A, Kunos G (1999) Cannabinoid-induced mesenteric vasodilation through an endothelial site distinct from CB1 or CB2 receptors. Proc Natl Acad Sci USA 96:14136–14141PubMedCrossRefGoogle Scholar
  20. Kennedy SH, Javanmard M, Vaccarino FJ (1997) A review of functional neuroimaging in mood disorders: positron emission tomography and depression. Can J Psychiatry 42:467–475PubMedGoogle Scholar
  21. Kwiatkowska M, Parker LA, Burton P, Mechoulam R (2004) A comparative analysis of the potential of cannabinoids and ondansetron to suppress cisplatin-induced emesis in the Suncus murinus (house musk shrew). Psychopharmacology (Berl) 174:254–259CrossRefGoogle Scholar
  22. Lemos JI, Resstel LB, Guimarães FS (2010) Involvement of the prelimbic prefrontal cortex on cannabidiol-induced attenuation of contextual conditioned fear in rats. Behav Brain Res 207:105–111PubMedCrossRefGoogle Scholar
  23. Li XB, Inoue T, Hashimoto S, Koyama T (2001) Effect of chronic administration of flesinoxan and fluvoxamine on freezing behavior induced by conditioned fear. Eur J Pharmacol 425:43–50PubMedCrossRefGoogle Scholar
  24. Long LE, Chesworth R, Huang XF, McGregor IS, Arnold JC, Karl T (2009) A behavioural comparison of acute and chronic Delta9-tetrahydrocannabinol and cannabidiol in C57BL/6JArc mice. Int J Neuropsychopharmacol 13:1–16Google Scholar
  25. Lowry OH, Rosebrough NJ, Rarr AL, Randall RJ (1951) Protein measurement with the folin phenol reagent. J Biol Chem 193:265–275PubMedGoogle Scholar
  26. Magen I, Avraham Y, Ackerman Z, Vorobiev L, Mechoulam R, Berry EM (2009) Cannabidiol ameliorates cognitive and motor impairments in mice with bile duct ligation. J Hepatol 51:528–534PubMedCrossRefGoogle Scholar
  27. Malberg JE, Blendy JA (2005) Antidepressant action: to the nucleus and beyond. Trends Pharmacol Sci 26:631–638PubMedCrossRefGoogle Scholar
  28. Malfait AM, Gallily R, Sumariwalla PF, Malik AS, Andreakos E, Mechoulam R, Feldmann M (2000) The nonpsychoactive cannabis constituent cannabidiol is an oral anti-arthritic therapeutic in murine collagen-induced arthritis. Proc Natl Acad Sci USA 97:9561–9566PubMedCrossRefGoogle Scholar
  29. Martinowich K, Manji H, Lu B (2007) New insights into BDNF function in depression and anxiety. Nat Neurosci 10:1089–1093PubMedCrossRefGoogle Scholar
  30. Mechoulam R, Hanus L (2002) Cannabidiol: an overview of some chemical and pharmacological aspects. Part I: chemical aspects. Chem Phys Lipids 121:35–43PubMedCrossRefGoogle Scholar
  31. Moody TW, Merali Z, Crawley JN (1988) The effects of anxiolytics and other agents on rat grooming behavior. Ann N Y Acad Sci 525:281–290PubMedCrossRefGoogle Scholar
  32. Moreira FA, Aguiar DC, Guimaraes FS (2006) Anxiolytic-like effect of cannabidiol in the rat Vogel conflict test. Prog Neuropsychopharmacol Biol Psychiatry 30:1466–1471PubMedCrossRefGoogle Scholar
  33. Moreira FA, Aguiar DC, Campos AC, Lisboa SF, Terzian AL, Resstel LB, Guimaraes FS (2009) Antiaversive effects of cannabinoids: is the periaqueductal gray involved? Neural Plast 2009:625469PubMedCrossRefGoogle Scholar
  34. Nestler EJ, Barrot M, DiLeone RJ, Eisch AJ, Gold SJ, Monteggia LM (2002) Neurobiology of depression. Neuron 34:13–25PubMedCrossRefGoogle Scholar
  35. Nibuya M, Morinobu S, Duman RS (1995) Regulation of BDNF and trkB mRNA in rat brain by chronic electroconvulsive seizure and antidepressant drug treatments. J Neurosci 15:7539–7547PubMedGoogle Scholar
  36. Nibuya M, Nestler EJ, Duman RS (1996) Chronic antidepressant administration increases the expression of cAMP response element binding protein (CREB) in rat hippocampus. J Neurosci 16:2365–2372PubMedGoogle Scholar
  37. Oka S, Nakajima K, Yamashita A, Kishimoto S, Sugiura T (2007) Identification of GPR55 as a lysophosphatidylinositol receptor. Biochem Biophys Res Comm 362:928–934PubMedCrossRefGoogle Scholar
  38. Oviedo A, Glowa J, Herkenham M (1993) Chronic cannabinoid administration alters cannabinoid receptor binding in rat brain: a quantitative autoradiographic study. Brain Res 616:293–302PubMedCrossRefGoogle Scholar
  39. Pardon MC, Roberts RE, Marsden CA, Bianchi M, Latif ML, Duxon MS, Kendall DA (2005) Social threat and novel cage stress-induced sustained extracellular-regulated kinase1/2 (ERK1/2) phosphorylation but differential modulation of brain-derived neurotrophic factor (BDNF) expression in the hippocampus of NMRI mice. Neuroscience 132:561–574PubMedCrossRefGoogle Scholar
  40. Patapoutian A, Reichardt LF (2001) Trk receptors: mediators of neurotrophin action. Curr Opin Neurobiol 11:272–280PubMedCrossRefGoogle Scholar
  41. Petitet F, Jeantaud B, Reibaud M, Imperato A, Dubroeucq M-C (1998) Complex pharmacology of natural cannabinoids: evidence for partial agonist activity of [Delta]9-tetrahydrocannabinol and antagonist activity of cannabidiol on rat brain cannabinoid receptors. Life Sci 63:PL1–PL6PubMedCrossRefGoogle Scholar
  42. Potter DJ, Clark P, Brown MB (2008) Potency of delta 9-THC and other cannabinoids in cannabis in England in 2005: implications for psychoactivity and pharmacology. J Forensic Sci 53:90–94Google Scholar
  43. Qin N, Neeper MP, Liu Y, Hutchinson TL, Lubin ML, Flores CM (2008) TRPV2 is activated by cannabidiol and mediates CGRP release in cultured rat dorsal root ganglion neurons. J Neurosci 28:6231–6238PubMedCrossRefGoogle Scholar
  44. Resstel LBM, Joca SRL, Moreira FA, Correa FMA, Guimaraes FS (2006) Effects of cannabidiol and diazepam on behavioural and cardiovascular responses induced by contextual conditioned fear in rats. Behav Brain research 172:294–298CrossRefGoogle Scholar
  45. Resstel LB, Tavares RF, Lisboa SF, Joca SR, Correa FM, Guimaraes FS (2009) 5-HT1A receptors are involved in the cannabidiol-induced attenuation of behavioural and cardiovascular responses to acute restraint stress in rats. Br J Pharmacol 156:181–188PubMedCrossRefGoogle Scholar
  46. Rock EM, Limebeer CL, Mechoulam R, Piomelli D, Parker LA (2008) The effect of cannabidiol and URB597 on conditioned gaping (a model of nausea) elicited by a lithium-paired context in the rat. Psychopharmacology (Berl) 196:389–395CrossRefGoogle Scholar
  47. Rudy JW, Huff NC, Matus-Amat P (2004) Understanding contextual fear conditioning: insights from a two-process model. Neurosci Biobehav Rev 28:675–685PubMedCrossRefGoogle Scholar
  48. Russo EB, McPartland JM (2003) Cannabis is more than simply ?9-tetrahydrocannabinol. Psychopharmacology 165:431–432PubMedGoogle Scholar
  49. Russo EB, Burnett A, Hall B, Parker KK (2005) Agonistic properties of cannabidiol at 5-HT1a receptors. Neurochem Res 30:1037–1043PubMedCrossRefGoogle Scholar
  50. Ryberg E, Larsson N, Sjogren S, Hjorth S, Hermansson NO, Leonova J, Elebring T, Nilsson K, Drmota T, Greasley PJ (2007) The orphan receptor GPR55 is a novel cannabinoid receptor. Br J Pharmacol 152:1092–1101PubMedCrossRefGoogle Scholar
  51. Sheline YI (2000) 3D MRI studies of neuroanatomic changes in unipolar major depression: the role of stress and medical comorbidity. Biol Psychiatry 48:791–800PubMedCrossRefGoogle Scholar
  52. Thome J, Sakai N, Shin KH, Steffen C, Zhang YJ, Impey S, Storm D, Duman RS (2000) cAMP response element-mediated gene transcription is upregulated by chronic antidepressant treatment. J Neurosci 20:4030–4036PubMedGoogle Scholar
  53. van Erp AMM, Kruk MR, Meelis W, Willekens-Bramer DC (1994) Effect of environmental stressors on time course, variability and form of self-grooming in the rat: handling, social contact, defeat, novelty, restraint and fur moistening. Behav Brain research 65:47–55CrossRefGoogle Scholar
  54. Wiley JL, Burston JJ, Leggett DC, Alekseeva OO, Razdan RK, Mahadevan A, Martin BR (2005) CB1 cannabinoid receptor-mediated modulation of food intake in mice. Br J Pharmacol 145:293–300PubMedCrossRefGoogle Scholar
  55. Williamson EM, Evans FJ (2000) Cannabinoids in clinical practice. Drugs 60:1303–1314PubMedCrossRefGoogle Scholar
  56. Zanelati TV, Biojone C, Moreira FA, Guimaraes FS, Joca SR (2010) Antidepressant-like effects of cannabidiol in mice: possible involvement of 5-HT1A receptors. Br J Pharmacol 159:122–128PubMedCrossRefGoogle Scholar
  57. Zuardi AW, Shirakawa I, Finkelfarb E (1982) Action of cannabidiol on the anxiety and other effects produced by delta 9-THC in normal subjects. Psychopharmacology 76:245–250PubMedCrossRefGoogle Scholar
  58. Zuardi AW, Crippa JAS, Hallak JEC, Moreira FA, Guimarães FS (2006) Cannabidiol, a Cannabis sativa constituent, as an antipsychotic drug. Braz J Med Biol Res 39:421–429PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag 2011

Authors and Affiliations

  • Maha M. ElBatsh
    • 1
    • 2
  • N. Assareh
    • 1
  • C. A. Marsden
    • 1
  • D. A. Kendall
    • 1
  1. 1.School of Biomedical Sciences, University of Nottingham Medical SchoolQueen’s Medical CentreNottinghamUK
  2. 2.Clinical Pharmacology Department, Faculty of MedicineMenofia UniversityShebin ElkomEgypt

Personalised recommendations